Unfortunately, neither the anti-NKG2A nor anti-MICA/MICB neutralizing antibodies have been evaluated in anti-HCC senescence-inducing treatment scenarios, which urges researchers to investigate their therapeutic roles in HCC. This evidence concerns the gene MICB and hepatocellular carcinoma.